Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 9/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.39 |
| ▸ | HTR6 | P50406 | 2/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.37 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.36 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | NMT1 | P30419 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21608527 | 0.80 | GRIN2B (0.48) | GRIN2BKCNH2TLR7MAPTRECQL | |
| SCHEMBL23531669 | 0.79 | EGLN1 (0.38) | TLR7HTR6RPS6KA5EGLN1 | |
| SCHEMBL23558166 | 0.74 | TLR7 (0.43) | GRIN2BKCNH2TLR7GABRA5GRIN1 | |
| SCHEMBL3449511 | 0.73 | RPS6KA5 (0.41) | HTR6RPS6KA5EGLN1 | |
| SCHEMBL8669239 | 0.72 | HTR6 (0.59) | HTR6EGLN1 | |
| SCHEMBL30881405 | 0.69 | L3MBTL1 (0.56) | MAPTBRD4 | |
| SCHEMBL27244169 | 0.69 | L3MBTL1 (0.56) | MAPTBRD4 | |
| SCHEMBL21608851 | 0.69 | GRIN2B (0.48) | GRIN2BKCNH2TLR7MAPTRECQL | |
| SCHEMBL23531728 | 0.68 | LMNA (0.45) | MAPT | |
| SCHEMBL23531701 | 0.67 | CYP17A1 (0.42) | HTR6RPS6KA5EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230099293-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2023-03-30 | — | — | US | disclosed |
| EP-4077323-A1 | OGA INHIBITOR COMPOUNDS | Janssen Pharmaceutica NV (BE) | 2022-10-26 | — | — | EP | disclosed |
| CN-114867725-A | OGA inhibitor compounds | 詹森药业有限公司 | 2022-08-05 | — | — | CN | disclosed |
| WO-2021123294-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2021-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230099293-A1 | OGA INHIBITOR COMPOUNDS | OGA, OGT, GRN | GRIN2B 614/4885KCNH2 4103/4885TLR7 4803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.